ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Clinical trial NCT00144911 · COMPLETED

Trial details

NCT number: NCT00144911
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Pulmonary Disease, Chronic Obstructive

Start date: 2004-10-01
Primary completion: 2006-12-01
Enrollment: 740

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.